Jurcic, J. G., Raza, A., Vlad, G., Stein, E. M., Roshal, M., Bixby, D. L., … Cortes, J. E. (2017). Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment. In BLOOD (Vol. 130). Atlanta, GA: AMER SOC HEMATOLOGY.

Jurcic, Joseph G., Azra Raza, George Vlad, Eytan M. Stein, Mikhail Roshal, Dale L. Bixby, Daniel F. Boyer, et al. “Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment.” In BLOOD, Vol. 130. AMER SOC HEMATOLOGY, 2017.

Jurcic JG, Raza A, Vlad G, Stein EM, Roshal M, Bixby DL, et al. Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment. In: BLOOD. AMER SOC HEMATOLOGY; 2017.

Jurcic, Joseph G., et al. “Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment.” BLOOD, vol. 130, AMER SOC HEMATOLOGY, 2017.

Jurcic JG, Raza A, Vlad G, Stein EM, Roshal M, Bixby DL, Boyer DF, Vigil CE, Syrbu S, Sekeres MA, Rogers HJ, Rizzieri DA, Lagoo AS, Roboz GJ, Redner RL, Steensma DP, Cook RJ, Moyo T, McKeown M, Waters NJ, Stephens K, Volkert A, Di Tomaso E, Roth DA, Cortes JE. Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment. BLOOD. AMER SOC HEMATOLOGY; 2017.